Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04701931 · ClinicalTrials.gov registry record
OCT Angiography Software Evaluation Study
A clinical trial of Retina Condition Followed by Fluorescein Angiography Imaging, sponsored by Topcon Corporation.
- Completed
- Registry status
- 135
- Enrollment target
- 2
- Study locations
NCT04701931: Completed study of Retina Condition Followed by Fluorescein Angiography Imaging, sponsored by Topcon Corporation.
NCT04701931 is a study of Retina Condition Followed by Fluorescein Angiography Imaging that has completed, run by Topcon Corporation. The registered enrollment target is 135 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04701931, a study of Retina Condition Followed by Fluorescein Angiography Imaging, has completed, sponsored by Topcon Corporation.
- COMPLETED
- Registry status
- 135 participants
- Enrollment target
- 2
- Study locations
Study Summary
Comparisons for vascular structure visualization in the retina and choroid.
Conditions Studied
Interventions
- DEVICE Maestro2 OCTA
- DEVICE Cirrus HD-OCT 5000
- DEVICE TRC-50DX
Study Locations (2)
California
- Orange County Retina Medical Group - Santa Ana
Georgia
- Southeast Retina Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2021-01-07 |
| Est. Completion | 2023-06-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04701931
The ClinicalTrials.gov registry entry for NCT04701931 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Topcon Corporation, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retina Condition Followed by Fluorescein Angiography Imaging appearing as the primary indexed condition, and to 3 interventions - of which Maestro2 OCTA is the first listed.
NCT04701931 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04701931 about?
NCT04701931 is a clinical study titled "OCT Angiography Software Evaluation Study". Comparisons for vascular structure visualization in the retina and choroid.
What is the current status of trial NCT04701931?
This trial is currently completed. The enrollment target is 135 participants. The study started on 2021-01-07. Estimated completion is 2023-06-06.
What conditions does trial NCT04701931 study?
This clinical trial studies the following conditions: Retina Condition Followed by Fluorescein Angiography Imaging.
What interventions are being tested in trial NCT04701931?
The interventions under investigation include: Maestro2 OCTA (DEVICE), Cirrus HD-OCT 5000 (DEVICE), TRC-50DX (DEVICE).
Who is sponsoring clinical trial NCT04701931?
This trial is sponsored by Topcon Corporation, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04701931 being conducted?
This trial has 2 study locations across California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.